Capital Planning LLC Sells 7,500 Shares of AbbVie Inc. $ABBV

Key Points

• Capital Planning LLC cut its AbbVie position by 38.6%, selling 7,500 shares in the third quarter and retaining 11,916 shares valued at approximately $3.12 million.
• AbbVie reported quarterly revenue of $16.99 billion, up 10.2% year over year, and earnings of $3.65 per share, exceeding analyst estimates as newer products offset declining Humira sales.
• Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and a $277.18 average price target. AbbVie also declared a quarterly dividend of $1.73 per share, representing a 2.5% annualized yield.

Capital Planning LLC reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 38.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,916 shares of the company's stock after selling 7,500 shares during the quarter. AbbVie accounts for about 0.9% of Capital Planning LLC's holdings, making the stock its 27th biggest holding. Capital Planning LLC's holdings in AbbVie were worth $3,117,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ABBV. Burk Holdings LLC acquired a new position in AbbVie during the second quarter worth about $30,000. Marquette Asset Management LLC raised its stake in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after buying an additional 48 shares during the last quarter. Abound Financial LLC acquired a new stake in AbbVie in the fourth quarter worth about $32,000. Principia Wealth Advisory LLC grew its stake in shares of AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock worth $40,000 after acquiring an additional 44 shares during the last quarter. Finally, Merkkuri Wealth Advisors LLC acquired a new position in shares of AbbVie during the first quarter valued at about $34,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of AbbVie stock opened at $276.24 on Friday. The firm has a 50-day simple moving average of $259.06 and a two-hundred day simple moving average of $236.63. The company has a market cap of $488.06 billion, a P/E ratio of 78.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.24. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $277.60.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts forecast that AbbVie Inc. will post 13.97 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie's payout ratio is 195.48%.

Analysts Set New Price Targets

Several brokerages recently commented on ABBV. Morgan Stanley increased their price objective on shares of AbbVie from $296.00 to $310.00 and gave the company an "overweight" rating in a research report on Wednesday. Scotiabank upped their price target on shares of AbbVie from $280.00 to $320.00 and gave the company an "outperform" rating in a research note on Tuesday. Cantor Fitzgerald raised their price target on shares of AbbVie from $285.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday. HSBC lifted their price objective on shares of AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Finally, BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus target price of $277.18.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen AbbVie’s oncology pipeline. The FDA granted two Breakthrough Therapy designations to Temab-A (telisotuzumab adizutecan) for colorectal cancer and non-small cell lung cancer. The designation can accelerate development and regulatory review, although it does not guarantee approval or commercial success. AbbVie’s Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
• Positive Sentiment: Analysts raised their valuation targets. JPMorgan increased its target to $300 and maintained an overweight rating, while Cantor Fitzgerald lifted its target to $290 and Guggenheim reaffirmed a buy rating with a $288 target. These actions suggest analysts see additional upside from AbbVie’s growth products and pipeline. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Positive Sentiment: New products are more than offsetting Humira’s patent-loss decline. Humira revenue fell 35.9% to $756 million, but total quarterly revenue rose 10.2% to $16.99 billion. The performance indicates that immunology, neuroscience and other newer medicines are successfully replacing the former blockbuster. AbbVie Outgrew Humira’s Collapse
• Neutral Sentiment: Valuation and income appeal remain part of the debate. AbbVie’s dividend and defensive characteristics may attract income-focused investors, but the stock’s elevated valuation means continued earnings and pipeline execution are important to justify further gains. Treasury Bills or Dividend Stocks

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.